Raymond James analyst Steven Seedhouse lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $75.00 (from $78.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Apellis Pharmaceuticals (APLS) PT Lowered to $29 at WedbushMarch 3, 2025 6:36 AM Apellis Pharmaceuticals (APLS) PT Lowered to $32 at Goldman SachsMarch 3, 2025 6:28 AM Apellis Pharmaceuticals (APLS) PT Lowered to $60 at StifelFebruary 28, 2025 3:25 PM TD Cowen Reiterates Buy Rating on Apellis Pharmaceuticals (APLS)February 28, 2025 3:06 PM Form S-8 Apellis Pharmaceuticals, February 28, 2025 7:22 AM Apellis Pharmaceuticals, Inc. (APLS) Tops Q4 EPS by 8cFebruary 28, 2025 7:11 AM Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 28, 2025 7:05 AM Form 10-K Apellis Pharmaceuticals, For: Dec 31February 28, 2025 7:01 AM